OKYO Pharma Limited (OKYO)
| Bid | 1.35 |
| Market Cap | 46.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.09K |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -3.63 |
| Forward PE | -12.31 |
| Analyst | Buy |
| Ask | 1.4 |
| Volume | 35,364 |
| Avg. Volume (20D) | 106,130 |
| Open | 1.60 |
| Previous Close | 1.56 |
| Day's Range | 1.38 - 1.60 |
| 52-Week Range | 0.81 - 1.74 |
| Beta | -4.15 |
About OKYO
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incor...
Analyst Forecast
According to 1 analyst ratings, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 407.25% from the latest price.
Stock Forecasts
22 hours ago · proactiveinvestors.com
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular c...
1 day ago · proactiveinvestors.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phas...
3 weeks ago · proactiveinvestors.com
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIOKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the c...
1 month ago · proactiveinvestors.com
OKYO Pharma reports long-term shelf stability of corneal pain treatmentOKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confi...
1 month ago · proactiveinvestors.com
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentOKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pa...
2 months ago · proactiveinvestors.com
OKYO Pharma secures USAN designation ‘urcosimod' for lead assetOKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in dev...